Posted by Michael Wonder on 15 Mar 2018
ICER finds emicizumab reduces treatment cost while improving health of people with haemophilia A
15 March 2018 - Report will be subject to public deliberation during New England CEPAC meeting on 29 March 2018.
The ICER today released an Evidence Report assessing the comparative clinical effectiveness and value of emicizumab (Hemlibra, Genentech). The report found that emicizumab offers important improvements in outcomes for people with haemophilia A and inhibitors to Factor VIII, while lowering costs associated with the treatment of this condition.
Emicizumab was approved by the FDA in November of 2017 for prophylaxis (prevention of bleeding) in adults and children who have haemophilia A with coagulation factor VIII inhibitors. Factor VIII is the clotting protein that is deficient in those with haemophilia A, and inhibitors interfere with the factor replacement therapy that would typically be used to treat the condition.
